Reviewed November 16, 2026

Ro

Private
ro.co

Direct-to-consumer telehealth

Company overview

Revenue
~$3.02B run rate
October 2026 · Estimate
Reference valuation
$7B
Historical financing · Feb 2022
Primary customer
Patients seeking weight management[1]
Commercial model
Telehealth and medication-related revenue[1]

Revenue is an independently estimated measure. The valuation is a dated transaction reference, not a current appraisal.[1]

Revenue history

Revenue

Annualized revenue · USD

+1,158%

Oct 2026 vs. Dec 2022 · calculated change; not annualized

$0$2B$4BDec 2022Dec 2023Dec 2024Dec 2025Oct 2026
Revenue observations and evidence
PeriodUSDEvidence
$240MEstimate
$258MEstimate
$526MEstimate
$875MEstimate
$3.02BEstimate

Sacra · company research and financial history ↗

Annualized revenue observations are point-in-time measures, not completed annual revenue.

Points show dated observations at equal spacing; intervening performance is not measured.

Products, customers & revenue model

ProductCustomerCommercial model
Body[1]Patients seeking weight management

Telehealth and medication-related revenue

Digital care[1]Consumers

Online care and fulfillment

Business economics

What drives the business
The revenue recovery followed the GLP-1 expansion. Medication-related sales should not be treated as software revenue.[1]

Leadership & functional coverage

Selected leaders supported by the linked sources; dated appointments retain their source context. This is not a complete org chart. Advisory roles are labeled.

LeaderRoleFunction / context
Zach ReitanoCofounder & CEOCompany leadership[2]
Sam ChaiVP, Clinical Strategy & Scientific AffairsClinical strategy[3]
Casey StackwickSenior Director, Pharmacy OperationsPharmacy operations[3]
Scott BachandCIO / CISOIT & security · June 2026 event[4]

Dated financial disclosures

DateEvent
October 2026~$3.02B run rate[1]

Estimate. Revenue observation; separate from the financing date.

Feb 2022$7B reference valuation[1]

Historical financing

Sector comparison

Same vertical; different business models and reporting periods. Values are not directly comparable revenue multiples.

CompanyRevenue measureReference valuation
Ro~$3.02B run rate

October 2026

$7B

Feb 2022

Devoted Health~$3.27B revenue

FY2024

$25B

Oct 2026

OpenEvidence~$300M run rate

July 2026

$15B

Sep 2026

Commure~$105M ARR

March 2024

$7B

May 2026

Abridge~$100M ARR

May 2025

$5.3B

Jun 2025

Open research questions

  • ↗What contribution margin remains after medications, care delivery and acquisition costs?

Sources & definitions

Financial history preserves the source’s measurement basis. ARR, annualized revenue, completed-year sales and transaction volume are distinct. Product economics are Plank analysis of the cited business model; open questions are not asserted findings.

  1. 1Sacra · company research and financial history
  2. 2Company · leadership directory or appointment
  3. 3Company · leadership directory or appointment
  4. 4Company · leadership directory or appointment